Unknown OBSERVATIONAL NCT03204838

IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients

STUDY TITLE IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients and Myelodysplasticsyndromes, Clinical Response to Treatment

Sponsor: Hospital General de Mexico

Conditions Acute Myeloid Leukemia (AML)

Interventions IDH mutation test performed at diagnosis

Updated 10 times since 2017 Last updated: Jun 28, 2017 Started: Jul 10, 2017 Primary completion: Dec 31, 2019 Completion: May 5, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Acute Myeloid Leukemia (AML), this trial is ongoing. The trial is conducted by Hospital General de Mexico and has accumulated 10 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Dec 2021 — Jul 2024 [monthly]

Unknown Status
Jan 2021 — Dec 2021 [monthly]

Unknown Status
Nov 2020 — Jan 2021 [monthly]

Unknown Status

▶ Show 5 earlier versions

Jun 2020 — Nov 2020 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jun 2018 — Jun 2020 [monthly]

Recruiting
May 2018 — Jun 2018 [monthly]

Recruiting
Apr 2018 — May 2018 [monthly]

Recruiting

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Recruiting NA

First recorded

Jul 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital General de Mexico

Data source: Hospital General de Mexico

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mexico City, Mexico